Global Hypophosphatemia Treatment Market, By Treatment (Medication, Surgical, Orthopaedic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Hypophosphatemia Treatment Market Analysis and Size
According to the statistics published in 2017 by the FDA, hypophosphatemia affected approximately 3,000 children and 12,000 adults in the U.S. The disorder is generally diagnosed in children with symptoms such as bent or bowed legs, severe dental and bone pain, and short stature. As per the National Center for Biotechnology Information (NCBI), in U.S. about 11-15% of the population are diagnosed with hyperphosphatemia each year where the majority of the population are suffering from diabetes and CVD. These set of people are at high risk of getting hypophosphatemia.
Data Bridge Market Research analyses a growth rate in the hypophosphatemia treatment market in the forecast period 2023-2030. The expected CAGR of hypophosphatemia treatment market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 25.7 million in 2022, and it would grow upto USD 37.97 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hypophosphatemia Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Medication, Surgical, Orthopaedic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Kyowa Kirin Co., Ltd (Japan), Smith+Nephew (U.K.), Nestle (Switzerland), Pfizer, Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), ADM Animal Nutrition (U.S.), Ultragenyx Pharmaceutical (U.S.), Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China), Lilly (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Prospec-Tany Technogene Ltd (Israel)
|
|
Market Opportunities
|
|
Market Definition
Hyperphosphatemia is a type of condition in which an abnormal amount of phosphate is present in the blood. The abnormal amount of phosphate is typically witnessed in the population with chronic kidney disease and cardiovascular diseases. In patients suffering from chronic kidney diseases, hyperphosphatemia is a primary cause of mortality and morbidity. The abnormal level of phosphates in hypophosphatemia causes numerous complications in the body including bone pain, bone fractures, appetite loss and confusion.
Global Hypophosphatemia Treatment Market Dynamics
Drivers
- Increase R&D Activities
The increased R&D activities on hypophosphatemia causes the market to flourish. To overcome the burden of hyperphosphatemia, many treatment options have been studied and research has been carried out. Many phosphate-lowering hyperphosphatemia treatment approaches have been executed to manage and prevent hyperphosphatemia. This boosts the growth of the market.
- Rising Healthcare Expenditure
The increasing research funding towards several rare diseases such as X-Linked Hypophosphatemia (XLH) and the high healthcare expenditure is also projected to increase the growth of the market during the forecast period. For instance, Genome Canada and the Canadian Institutes for Health Research entered into a partnership to study rare genetic diseases by using Next-Generation Sequencing (NGS) technology. Thus, this factor has impacted in a huge growth of the market.
Opportunities
- Increase in Elderly Population
The market is estimated to witness a heavy growth rate in the forecast period driven by the factor of an aging population. The increasing demand in the market is the replication of increasing elderly population, as people aged over 60 years often develop low immunity conditions affecting the normal functioning. This boost the market growth.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified healthcare professional unable to perform the treatments could reduce the growth of the hypophosphatemia treatment market during the forecast period.
- Side-Effects of Hypophosphatemia Treatment
The adverse side-effects associated with the treatment process hinder the market growth. Effects such as hearing loss, infections and also some drugs can lead to autoimmune reactions.
This hypophosphatemia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hypophosphatemia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Hypophosphatemia Treatment Market Scope
The hypophosphatemia treatment market is segmented on the basis of treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Medication
- Surgical
- Orthopaedic
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Hypophosphatemia Treatment Market Regional Analysis/Insights
The hypophosphatemia treatment market is analyzed and market size insights and trends are provided by treatment, distribution channel and end-user as referenced above.
The major countries covered in the hypophosphatemia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for hypophosphatemia treatment market throughout the forecasted period due to high presence of key manufacturers of the product and, increasing research and development activities.
Asia-Pacific dominates the market due to increased new research and developments.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hypophosphatemia Treatment Market Share Analysis
The hypophosphatemia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hypophosphatemia treatment market.
Key players operating in the hypophosphatemia treatment market include:
- Kyowa Kirin Co., Ltd (Japan
- Smith+Nephew (U.K.)
- Nestle (Switzerland)
- Pfizer, Inc. (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- ADM Animal Nutrition (U.S.)
- Ultragenyx Pharmaceutical (U.S.)
- Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China)
- Lilly (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Prospec-Tany Technogene Ltd (Israel)
SKU-